TY - JOUR
T1 - Maximizing the effectiveness of oral therapies in lymphoid cancers
T2 - research gaps and unmet needs
AU - Zackon, Alix Y.L.
AU - Ayers, Amy A.
AU - Yeager, Katherine A.
AU - Somma, Mary L.
AU - Friedberg, Jonathan W.
AU - Flowers, Christopher R.
AU - Nastoupil, Loretta J.
N1 - Funding Information:
Research reported in this publication was supported in part by National Cancer Institute Awards K24CA208132 and U01CA195568. Also funding was received from Alliance for Clinical Trials in Oncology Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/8/24
Y1 - 2019/8/24
N2 - Oral therapies have become a common treatment choice for several lymphoid cancers. While therapeutic efficacy and patient preference for this therapy type have been reported, there is a lack of knowledge about its effectiveness for lymphoma in clinical practice, particularly in regard to the effects of medication nonadherence. While studies of oral medications in other diseases have shown that adherence is a major factor in outcomes and costs, there is scant research investigating adherence specifically in lymphoma patients, who face unique challenges in their diseases and treatments. To address the limited data available, we constructed a conceptual model and highlighted key opportunities for future research to better elucidate oral therapy adherence in lymphoma. This research will hopefully improve understanding and efficacy of oral treatment for lymphoma patients, while also informing other cancers utilizing oral therapies currently and in the future.
AB - Oral therapies have become a common treatment choice for several lymphoid cancers. While therapeutic efficacy and patient preference for this therapy type have been reported, there is a lack of knowledge about its effectiveness for lymphoma in clinical practice, particularly in regard to the effects of medication nonadherence. While studies of oral medications in other diseases have shown that adherence is a major factor in outcomes and costs, there is scant research investigating adherence specifically in lymphoma patients, who face unique challenges in their diseases and treatments. To address the limited data available, we constructed a conceptual model and highlighted key opportunities for future research to better elucidate oral therapy adherence in lymphoma. This research will hopefully improve understanding and efficacy of oral treatment for lymphoma patients, while also informing other cancers utilizing oral therapies currently and in the future.
KW - Oral therapy
KW - adherence
KW - lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85073183297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073183297&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1594217
DO - 10.1080/10428194.2019.1594217
M3 - Review article
C2 - 31164024
AN - SCOPUS:85073183297
SN - 1042-8194
VL - 60
SP - 2356
EP - 2364
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 10
ER -